Professor Constantin Coussios is the Director of the Oxford Institute of Biomedical Engineering. He received his BA, MEng and PhD in Engineering from the University of Cambridge and was elected to the first statutory chair in Biomedical Engineering at the University of Oxford in 2011, with special responsibility for drug delivery and therapeutic devices. He founded and heads the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL), a research group of some 50 researchers today housed in the Marcela wing of the Botnar Research Centre.

Between 2014 and 2021, he served as Director of the £11m Oxford Centre for Drug Delivery Devices (OxCD³) supported by a national programme grant from the UK’s Engineering and Physical Sciences Research Council in collaboration with the pharmaceutical and medical device industry to improve oncological drug delivery: during this period, he led TarDox, a first-in-human trial of ultrasound-triggered targeted drug delivery in patients with liver tumours (Lancet Oncology 2018). In 2021, he became the founding director of the Podium Institute for Sports Medicine and Technology, supported by a £25m benefaction to the University.

Prof. Coussios received the UK’s Institute of Acoustics’ Young Person’s Award for Innovation in Acoustical Engineering in 2007, was elected as Secretary-General of the International Society for Therapeutic Ultrasound between 2006-2010 and was honoured with the Society’s Fred Lizzi award in 2012. He was elected as the youngest ever Fellow of the Acoustical Society of America in 2009, and received the Society’s Bruce Lindsay award in 2012. In 2008, he was one of two academic founders of the Oxford University spin-out OrganOx Ltd., which has developed a novel normothermic perfusion device for improved liver and kidney preservation prior to transplantation through to randomized trials (Nature 2018), CE marking and FDA approval, NICE approval and successful commercilization.

In 2014, he co-founded OxSonics Ltd, which is commercializing cavitation-enhanced oncological drug delivery, and in 2016 he co-founded OrthoSon Ltd, which is developing minimally invasive replacement of the intervertebral disc. He received the Silver Medal of the Royal Academy of Engineering in 2017 for contributions to the translation of novel medical technologies into clinical practice, was elected a Fellow of the Academy in 2019, and awarded an OBE in 2022 for services to biomedical engineering.